KALA BIO, Inc. (KALA) P/E Ratio History
Deep ValueTrading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2023–2023
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, KALA BIO, Inc. (KALA) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.16 and trailing twelve-month earnings per share of $-135.92.
The current P/E is 100% below its 5-year average of 9118.8x. Over the past five years, KALA's P/E has ranged from a low of 9118.8x to a high of 9118.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, KALA trades at a 100% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, KALA trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KALA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KALA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
KALA P/E vs Peers
Front-of-Eye Drugs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 25.5Lowest | -Best | -22%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
KALA Historical P/E Data (2023–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q2 | Jun 30 2023 | $729.50 | $0.08 | 9118.8x | +0% |
Average P/E for displayed period: 9118.8x
KALA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KALA — Frequently Asked Questions
Quick answers to the most common questions about buying KALA stock.
What is KALA's P/E ratio?
KALA BIO, Inc. (KALA) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-135.92. The 5-year average P/E is 9118.8x and the historical range spans 9118.8x to 9118.8x.
Is KALA stock overvalued or undervalued?
KALA current P/E: -0.0x. 5-year average P/E: 9118.8x. Percentile: 0th.
Is KALA stock expensive?
KALA is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 9118.8x (0th percentile of historical range).
What is KALA's historical P/E range?
Over the past 5 years, KALA's P/E ratio has ranged from 9118.8x to 9118.8x, with a median of 9118.8x and an average of 9118.8x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 2023–2023.
How does KALA's P/E compare to the S&P 500?
KALA current P/E: -0.0x. S&P 500 median P/E: 21.8x.
How does KALA's valuation compare to Healthcare peers?
KALA BIO, Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is KALA's PEG ratio?
KALA PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 67.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is KALA's earnings yield?
KALA earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.